x
- Home
- Diabetes Models
- In Vivo Models of Diabetes Mellitus
- In Vitro Models of Diabetes Mellitus
- Diabetes Drug R&D Services
- Therapeutic Areas
- Virtual Booth
- Company
Insulin secretagogues provide an effective diabetes treatment option. Ace Therapeutics is committed to applying our expertise in antidiabetic drug discovery to help our clients develop safe and effective insulin secretagogues. Our dedicated drug discovery team utilizes target-based antidiabetic drug screening and discovery technologies to help clients rapidly identify promising insulin secretagogues.
Insulin secretagogues are an important class of antidiabetic drugs, mainly including sulfonylureas, non-sulfonylureas and novel small-molecule insulin secretagogues. These drugs work by stimulating β-cells to secrete more insulin. Insulin secretagogues have good therapeutic effects on people with type 2 diabetes who still retain some islet function. Therefore, the continuous search for safer and more effective insulin secretagogues not only enriches the arsenal of drugs for diabetes treatment, but also opens up more possibilities for innovative therapies in the future.
Fig. 1 Mechanism of action of sulfonylureas.
(Su, J.; et al., 2024)
The experts at Ace Therapeutics have extensive expertise and experience in insulin secretagogue development and drug discovery. We are committed to providing our clients with tailored drug discovery solutions to help them develop more efficient insulin secretagogues.
Sulfonylurea Development Services
The mechanism of action of sulfonylureas is that they exert glucose-lowering effects by binding to sulfonylurea receptors on pancreatic β-cells and stimulating their secretion of insulin. Based on this mechanism, we provide the following drug discovery and development services to our clients.
We provide sulfonylurea screening and optimization services to help our clients discover drug molecules with insulinotropic activity.
We analyze and validate sulfonylurea binding to sulfonylurea receptors to ensure drug specificity.
We provide comprehensive in vitro and in vivo activity assessment to ensure the efficacy and safety of potential sulfonylureas.
Our goal is to help our clients discover sulfonylureas with favorable glucose-lowering effects, insulin sensitization, and reduced or delayed onset of chronic complications of type 2 diabetes.
Non-Sulfonylureas Development Services
Non-sulfonylurea insulinotropic agents, also known as glinides or glinides, are a type of pharmaceutical agent used to treat diabetes. Glinides selectively bind to SUR1 on pancreatic β-cells, stimulating insulin release by closing ATP-sensitive K channels. Our non-sulfonylurea drug development capabilities include:
We utilize in vitro high-throughput screening to test the insulinotropic effect of non-sulfonylureas, with the objective of identifying compounds with enhanced activity.
We assess the potential of non-sulfonylureas to bind to SUR1 on pancreatic β-cells, with the objective of ensuring drug specificity.
We provide structural modification services for non-sulfonylureas with the objective of optimizing their specificity for SUR1 and improving their insulin secretory activity.
We utilize in vivo studies to assist our clients in conducting a more comprehensive analysis of the efficacy and safety of their non-sulfonylurea drug candidates.
Other Novel Insulin Secretagogues Development Services
We also provide screening, optimization, activity evaluation and safety assessment services for other novel insulin secretagogues. These drugs include GPCR agonists, protein tyrosine phosphatase-1B (PTP1B) inhibitors, and others.
Advantages of Our Insulin Secretagogues Development Services
Ace Therapeutics is committed to providing clients with expert insulin secretagogues development solutions to accelerate their antidiabetic drug development programs. Please contact us for more details. Our experts will collaborate with you to advance the field of diabetes.
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
